ОбзорГрафикНовостиTraderScreen

Morgan Stanley Knock-Out NOVN/  DE000MG2R7K9  /

Stuttgart
13.11.2024  21:05:40 Изменение-0.04 Бид22:00:36 Предложение22:00:36 Базовый актив Цена исполнения Дата истечения Тип опциона
4.02EUR -0.99% -
Величина цены спроса: -		 -
Величина цены предложения: -		 NOVARTIS N 54.3923 CHF 31.12.2078 Call
TeleTrader 29.10 Novartis' Q2 EPS surge by 116% to $1.58
GlobeNewswire 30.07 Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
TeleTrader 18.07 Novartis Q2 EPS up 47% to $1.60
GlobeNewswire 08.07 Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire 26.06 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 13.06 Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire 29.05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 13.05 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
TeleTrader 02.05 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 23.04 Novartis up 5% on upbeat guidance, earnings
TeleTrader 23.04 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 16.04 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire 11.04 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
TeleTrader 11.04 Novartis launches offer for Morphosys at €68 per share
TeleTrader 09.04 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 14.03 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 12.03 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 28.02 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire 28.02 PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
TeleTrader 05.02 Novartis to acquire MorphoSys for $2.9B
TeleTrader 31.01 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 10.01 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 05.01 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 02.01 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 21.12.2023 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...